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EDITORIAL

Pregnancy and Kidney Disease: Crossroads No More

I

n this issue of Advances of Chronic Kidney Disease, the
Guest Editors, Susan Hou and Belinda Jim, have carried
to term 12 papers that that provide an up-to-date and
comprehensive set of directions for the intersections of
obstetrics and nephrology and hypertension. Like most
drivers, the rules of entry into an intersection are practiced more than recalled and performed exactly as once
taught and learned. Thus, preventable illness still occurs
in situations in which nephrological care could forestall
substantial morbidity and mortality to fetus and mother.
Some of the root cause of this gap in care may be attributed to the infrequency of exposure to the clinical crossroads—points of critical decision—between kidney and
pregnancy doctors. Another may be a lack of knowledge
and education regarding the nodes of care shared by
nephrologists and obstetricians. Although this may be
unfortunately true, this circumstance is far superior to
that of the 19th century, during which time the birthing
process had nearly been debranched from the tree of
medicine, solely relegated to the practice of midwives.1
However, given newer developments regarding the physiology and pathophysiology of the gravid state, the nephrologist can no longer wait dispassionately for those
obstetrical consultations that involve an aggravation of
preexisting or de novo hypertension or kidney illness.
Such passivity results in a disjunction of clinical care,
benefiting no one.
Aside from anemia, typically from iron deficiency,
and edema, hypertension during pregnancy remains
the most common medical complication of pregnancy.
However, hypertension is present in up to 10% of pregnancies2 and affects nearly one-quarter million pregnancies annually in the United States. High blood pressure
complicates the gravid state and can be subdivided into
two categories as specified by a recent Canadian classification: (1) preexisting for blood pressure elevations
exceeding 140/90 mmHg before 20 weeks of pregnancy
or (2) gestational hypertension occurring after the 20th
week of pregnancy.3 Either category may be complicated
by preeclampsia, although this classification is skewed

toward the observation that preeclampsia generally
proceeds in the second half of pregnancy. This schema
simplifies the age-worn categorization espoused by the
National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy that
had four categories: chronic hypertension, preeclampsiaeclampsia, preeclampsia superimposed on chronic hypertension, and gestational hypertension.4 The time-based,
Canadian system assumes that the patient-mother either
had prehypertension, essential hypertension, or a chronic
kidney disorder aggravated by pregnancy if the blood
pressure increased within 20 weeks of gestation. After
that point, a pathophysiological state of pregnancy is
presumed such as preeclampsia, although quite rarely
this disorder may occur in the initial trimester in association with hydatidiform mole. The former U.S. system
overarches the Canadian system, but neither one truly
defines etiopathogenesis except where obvious. Thus,
an appropriate differential diagnosis is an imperative
while keeping in mind that CKD may have been
masked or missed.
The treatment of severely elevated blood pressure during pregnancy is still to an as yet unknown ideal target,
and therapy is subservient to diagnosis. The number of
approved antihypertensive agents for pregnancy is relatively few, and there is neither priority nor persuasion
to determine newer drugs. Experience has shown that
first- and second-line agents can be safely used at conventionally prescribed doses. Thus, we are constrained to
first-line therapy with methyldopa and second-line
treatment by labetalol, nifedipine, beta-blockers, thiazide
diuretics, or hydralazine.1 However, this U.S. Food and
Drug Administration espoused therapeutic order has
been challenged. Methyldopa, with its serious adverse
effect profile and spotty efficacy, is often displaced to
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second-line therapy and replaced by labetalol and
nifedipine as first-line antihypertensives by experienced,
practicing clinicians. It is important to note that the
blood pressure target may even be disputed because
high-quality clinical trials to establish the appropriate
blood pressure target are lacking. Nevertheless, blood
pressure monitoring is critical and is augmented by
ambulatory blood pressure measurements and home
blood pressure monitoring systems. However, with preeclampsia, treatment determination via conventional
blood pressure measurement by sphygmomanometry
remains the standard.1
Pregnancy is typified by enhanced glomerular filtration and expanded volume; serum creatinine concentration falls, along with the blood urea nitrogen, serum
urate concentration, and bicarbonate level. The latter reflects not a metabolic acidosis but a chronic respiratory
alkalosis with purposeful hyperchloremia.5 As a corollary, a normal or mildly increased creatinine level indicates disease status. Acute kidney injury may occur
during pregnancy, and the etiology may derive from
any of many disorders, including acute tubular necrosis;
glomerulopathies, in particular those of an autoimmune
nature that strike women in a disproportionate fashion;
kidney stones; obstruction with or without infection;
and thrombotic microangiopathies.6 Discriminating diagnostic acumen is essential. The notation of proteinuria
facilitates the differential diagnosis but establishes no diagnosis, and reticence to perform a kidney biopsy may
have to be overcome. The relative inability to use cytotoxic agents during pregnancy must not be mistaken as
motivation to blindly substitute glucocorticoid steroids
to suppress urinary protein excretion when a diagnosis
has not been ascertained. However, cytotoxic therapy
should not be withheld when the mother’s life is at
stake, as might be the case of the pregnant lupus patient.
It is gratifying that steroid therapy is relatively safe
in pregnancy and relatively infrequently precipitates
hypertension.
One of the challenges for kidney physicians is to discriminate whether pregnancy has aggravated or unmasked
preexistent CKD, which may be as yet undisclosed glomerular disease or hypertensive disease. Although a prepregnancy serum creatinine level of 1.4 mg/dL has served
as a threshold for CKD in pregnant females,4 this threshold
was determined when there were multiple, unstandardized creatinine assays and estimating glomerular filtration
rate equations were not utilized. Individuals with serum
creatinine levels of 1.4 mg/dL or greater are at higher
risk for kidney functional deterioration than those with
creatinine levels below this threshold concentration. Today,
the standardized serum creatinine registers lower than it
would have 5 years ago.7 Consequently, a decline in kidney
function at a lower serum creatinine level is plausible and
should be anticipated. With no clinically convenient
method to evaluate kidney reserve, it is impossible to dis-

tinguish the manner in which two patients with a serum
creatinine level of, per se, 1.2 mg/dL respond to the hemodynamic changes imposed by the gravid state, namely
those of hypervolemia, reduced vascular resistance, and
increased glomerular filtration rate. Essentially, deterioration may occur in the individual with unknown CKD
whereas the other is none the worse for wear.
Preeclampsia also obfuscates the diagnosis of CKD
during pregnancy and threatens fetus and mother. Establishing this diagnosis is paramount for protection
of the mother and child. It is important to note that
peripheral edema is no longer required in this disorder,
which is characterized by a relatively restricted extracellular fluid volume in an environment of increased
vascular resistance.8 The disorder was previously
treated only symptomatically and in relative ignorance.
Aspirin may be preventive in high-risk cases of preeclampsia, but calcium is not.9 The fascinating pathobiology of this microangiopathic, thrombotic glomerular
endothelial disorder has been unraveled as a relative
deficiency of bioactively available placental growth
factor (PlGF). This principal, nurturing, angiogenic
hormone of placental maturation has properties akin
to those of the vascular endothelial growth factors
(VEGFs). The fundamental defect is a surfeit of circulating soluble fms-like tyrosine kinase-1 (sFlt1)—soluble
VEGF receptor-1.10,11 In targeted translational studies,
the placental trophoblast was determined to drive the
excessive sFlt1 levels after exponential elevations of
this protein’s message were revealed by gene chip
array analyses of whole placentas obtained from
preeclamptic individuals by Maynard while working
in the laboratory of Karumanchi. The sFlt1 decoy
receptor scavenges the placental molecule, thereby
abrogating its salutary vasculogenic effects. The PlGF
deficiency conspires with elevated soluble endoglin
levels that impair transforming growth factor b-1
signaling to reproduce the experimental preeclamptic
phenotype in affected females.12 It is remarkable that
PlGF levels may be depressed quite early in gestation,
resolving the question of why preeclampsia is not
solely confined to the latter half of pregnancy.
The above observations neatly coincided with the
thrombotic microangiopathy, podocytopathy, and
hypertension associated with therapeutic VEGF
immuno-interruption by anti-VEGF antibodies such as
bevacizumab, as delineated by Jefferson and recapitulated by Eremina and colleagues in a podocyte-specific
VEGF knockout mouse model.13 Lastly, with the prospect of earlier diagnosis of preeclampsia by laboratory
examination of circulating PlGF, endoglin, and sFlt1
levels14,15 and the possibility of intervention by sFlt1
adsorptive therapy, there is more hope for this
complex disorder than hitherto imagined.16 The recent
notation that elevated sFlt1 levels are apparent in
CKD and induce endothelial dysfunction, endothelial
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apoptosis, and antiangiogenic activity broadens the potential for anti-antiangiogenic therapy with anti-sFlt1
antibodies in preeclampsia and CKD.17,18
Aside from preeclampsia-eclampsia, does the newborn suffer when the kidneys of the mother incur multigravid hemodynamic stress? Piccoli and colleagues
recently investigated this clinically germane circumstance.19 The data from their exclusively Italian cohort
study of 314 mothers with CKD and multiple pregnancies were compared with those from a ‘‘healthy’’ cohort.
The health of the newborns was unfortunately compromised at multiple levels: preterm delivery (,34 weeks),
small-for-gestational-age babies, a requirement for neonatal intensive care, weight discordance between twins,
and neonatal and perinatal mortality. A separate, longitudinal report of the maternal parameters of kidney health/
disease is hopefully forthcoming in parallel with a larger
study of similar ilk that validates the Italian data.
Of interest is that nephrologists have forcefully driven
the recent contributions to the elucidation of the pathobiology of preeclampsia, its diagnosis, and its treatment.
These individuals certainly understand that kidney doctors play a vital role in the delivery of optimized care for
pregnant females with high blood pressure and/or kidney disease. Rather than meeting the obstetrician at
a crossroad and waiting passively for disease to extend
itself, the nephrologist must embrace a parallel path
with his/her colleague when such circumstances arise.

Acknowledgments
The author expresses gratitude to Sharon Maynard for her insightful commentary regarding this manuscript.

Jerry Yee, MD
Editor-in-Chief

References
1. Brodsky L. Where have all the midwives gone? J Perinat Educ.
2008;17(4):48-51.
2. Podymow J, August P. Update on the use of antihypertensive drugs
in pregnancy. Hypertension. 2008;51(4):960-969.

205

3. Magee LA, Helewa M, Moutquin J-M, et al. Diagnosis, evaluation,
and management of the hypertensive disorders of pregnancy. J Obstetrics Gynaecol Can. 2008;30(3):S1-S48.
4. Report of the National High Blood Pressure Education Program
Working Group on High Blood Pressure in Pregnancy. Am J Obstet
Gynecol. 2000;183(1):S1-S22.
5. Lim VS, Katz AI, Lindheimer MD. Acid-base regulation in pregnancy. Am J Physiol. 1976;231(6):1764-1769.
6. Krane NK. Acute renal failure in pregnancy. Arch Intern Med.
1988;148(11):2347-2357.
7. Peake M, Whiting M. Measurement of serum creatinine—current
status and future goals. Clin Biochem Rev. 2006;27(4):173-184.
8. Khalil RA, Granger JP. Vascular mechanisms of increased arterial
pressure in preeclampsia: lessons from animal models. Am J Physiol
Regul Integr Comp Physiol. 2002;283(1):R29-R45.
9. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337(2):69-76.
10. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fmslike tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest.
2003;111(5):649-658.
11. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic
factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):
672-683.
12. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):
642-649.
13. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and
renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):11291136.
14. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF
antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278(15):12605-12608.
15. Ohkuchi A, Hirashima C, Matsubara, et al. Threshold of soluble
fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension. 2011;58(5):859-866.
16. De Vivo A, Baviera G, Giordano D, et al. Endoglin, PlGF and sFlt-1
as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand.
2008;87(8):837-842.
17. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.
Circulation. 2011;124(8):940-950.
18. Di Marco GS, Reuter S, Hillebrand U, et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am
Soc Nephrol. 2009;20(10):2235-2245.
19. Piccoli GB, Arduino S, Attini R, et al. Multiple pregnancies in
CKD patients: an explosive mix. Clin J Am Soc Nephrol. 2013;8(1):
41-50.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

